Clinical Trial Update: Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Participants With Systemic Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating imatinib mesylate for systemic sclerosis showed results on efficacy and tolerability.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• STI571 (imatinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Systemic Sclerosis, Scleroderma | Phase 2 | Status: COMPLETED | Results posted: 2021-05-21